SCHEMBL6799467

SCHEMBL6799467

COc1cccc(/C=C2\N=C(c3ccc([N+](=O)[O-])cc3)OC2=O)c1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.61
PLCG2 P16885 1/20 0.54
DAPK3 O43293 1/20 0.53
ALDH1A1 P00352 6/20 0.52
MAPT P10636 5/20 0.52
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
TNNI3 P19429 1/20 0.49
CRHBP P24387 1/20 0.49
TNNT2 P45379 1/20 0.49
TNNC1 P63316 1/20 0.49
CRHR2 Q13324 1/20 0.49
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 1/20 0.45
NTSR1 P30989 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799468 1.00 ALOX5 (0.61) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL15689597 0.90 MEN1 (0.57) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL4688693 0.90 MEN1 (0.57) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL4688695 0.90 MEN1 (0.57) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL6796295 0.85 KMT2A (0.65) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL6796298 0.85 KMT2A (0.65) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL17176852 0.80 PLCG2 (0.61) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL30199710 0.80 PLCG2 (0.55) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL6794623 0.80 MASP2 (0.62) ALOX5PLCG2DAPK3ALDH1A1MAPT
SCHEMBL6794620 0.80 MASP2 (0.62) ALOX5PLCG2DAPK3ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 ALOX5 1156/4885PLCG2 4365/4885DAPK3 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.